Unresectable Or Metastatic Melanoma clinical trials

Explore recruiting unresectable or metastatic melanoma clinical trials.

Recruiting unresectable or metastatic melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Unresectable Or Metastatic Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma

Germany, Lithuania, Spain, Estonia, Italy, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab vs Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma

Romania, Finland, Austria, Italy, Germany, Belgium +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

Belgium, Germany, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, multicenter, randomized, open-label, parallel group, treatment study to assess the efficacy and safety of the lifileucel (LN-144, autologous tumor-infiltrating lymphocytes [TIL]) regimen in combination with pembrolizumab compared with pembrolizumab monotherapy in participants with untreated, unresectable or metastatic melanoma

Germany, France, Italy, Netherlands, Spain, Belgium +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants with Previously Untreated Unresectable or Metastatic Melanoma

Poland, Greece, Slovakia, Czechia, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment naïve adults with unresectable or metastatic melanoma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Unresectable Or Metastatic Melanoma trials by city

Unresectable Or Metastatic Melanoma in Toronto Unresectable Or Metastatic Melanoma in Vancouver Unresectable Or Metastatic Melanoma in Montreal Unresectable Or Metastatic Melanoma in Calgary Unresectable Or Metastatic Melanoma in Edmonton Unresectable Or Metastatic Melanoma in Ottawa Unresectable Or Metastatic Melanoma in Winnipeg Unresectable Or Metastatic Melanoma in Quebec City Unresectable Or Metastatic Melanoma in Hamilton Unresectable Or Metastatic Melanoma in Kitchener Unresectable Or Metastatic Melanoma in London Unresectable Or Metastatic Melanoma in Halifax Unresectable Or Metastatic Melanoma in New York Unresectable Or Metastatic Melanoma in Los Angeles Unresectable Or Metastatic Melanoma in Chicago Unresectable Or Metastatic Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease